Close this search box.

Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer’s Disease


Study First Submitted Date 2021-03-30
Study First Posted Date 2021-04-22
Last Update Posted Date 2022-05-06
Verification Month Year December 2020
Verification Date 2020-12-31
Last Update Posted Date 2022-05-06


Sequence: 51749019
Name Alzheimer Disease
Downcase Name alzheimer disease

Id Information

Sequence: 39821839
Id Source org_study_id
Id Value CTXSP0001


Sequence: 52070737
Intervention Type Drug
Name Adipose-Derived Mesenchymal Stem Cells


Sequence: 79176597
Name Autologous Adipose-derived Stem Cells (AdMSCs)
Downcase Name autologous adipose-derived stem cells (admscs)

Browse Conditions

Sequence: 191786132 Sequence: 191786133 Sequence: 191786134 Sequence: 191786135 Sequence: 191786136 Sequence: 191786137 Sequence: 191786138 Sequence: 191786139 Sequence: 191786140
Mesh Term Alzheimer Disease Mesh Term Dementia Mesh Term Brain Diseases Mesh Term Central Nervous System Diseases Mesh Term Nervous System Diseases Mesh Term Tauopathies Mesh Term Neurodegenerative Diseases Mesh Term Neurocognitive Disorders Mesh Term Mental Disorders
Downcase Mesh Term alzheimer disease Downcase Mesh Term dementia Downcase Mesh Term brain diseases Downcase Mesh Term central nervous system diseases Downcase Mesh Term nervous system diseases Downcase Mesh Term tauopathies Downcase Mesh Term neurodegenerative diseases Downcase Mesh Term neurocognitive disorders Downcase Mesh Term mental disorders
Mesh Type mesh-list Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor


Sequence: 47926977
Agency Class INDUSTRY
Lead Or Collaborator lead
Name Celltex Therapeutics Corporation

Overall Officials

Sequence: 29038871
Role Principal Investigator
Name Richard L Neel, M.D.
Affiliation Little Alsace Urgent Care Center


Sequence: 30518936
Minimum Age N/A
Maximum Age N/A
Criteria Inclusion Criteria: The patient is diagnosed with later stage of Alzheimer Disease with sever cognitive disability. All current anti-Alzheimer medicines cannot prevent disease progression and the patient's mental and physical ability persistently declined Patient's legal guardian and caregiver must voluntarily sign an approved written consent form after ample explanation of the proposed therapy. Exclusion Criteria: Current diagnosis of malignancy Renal/liver dysfunction: Exceed two times as normal subject Pregnant or nursing Received other trial drugs within 30 days after participation of this study Experienced major surgery or trauma in the last 14 days
Adult True
Child True
Older Adult True

Calculated Values

Sequence: 254075410
Registered In Calendar Year 2021
Were Results Reported False
Has Single Facility False

Responsible Parties

Sequence: 28648149
Responsible Party Type Sponsor